

## **CONTENTS**

Green International Holdings Limited • Interim Report 2022

Corporate Information	2
Condensed Consolidated Statement of Profit or Loss	4
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	5
Condensed Consolidated Statement of Financial Position	6
Condensed Consolidated Statement of Changes in Equity	8
Condensed Consolidated Statement of Cash Flows	9
Notes to the Condensed Consolidated Interim Financial Statements	10
Management Discussions and Analysis	28
Other Information	36

## **Corporate Information**

### **BOARD OF DIRECTORS**

### **Executive Directors**

Mr. Liu Dong Mr. Yu Xiangjin

### **Non-executive Directors**

Mr. Chen Hanhong

Mr. Yu Zhoujie (Chairman)

### Independent Non-executive Directors

Mr. Wu Hong Mr. David Tsoi Mr. Wang Chunlin

### **AUDIT COMMITTEE**

Mr. David Tsoi (Committee Chairman)

Mr. Wu Hong Mr. Wang Chunlin

#### REMUNERATION COMMITTEE

Mr. David Tsoi (Committee Chairman)

Mr. Yu Zhoujie Mr. Wu Hong Mr. Wang Chunlin

#### NOMINATION COMMITTEE

Mr. Yu Zhoujie (Committee Chairman)

Mr. David Tsoi Mr. Wu Hong Mr. Wang Chunlin

### AUTHORISED REPRESENTATIVES

Mr. Chen Hanhong Mr. Yu Zhoujie

### **COMPANY SECRETARY**

Mr. Tsang Kwok Wai

### **AUDITOR**

HLB Hodgson Impey Cheng Limited Certified Public Accountants 31st Floor, Gloucester Tower The Landmark, 11 Pedder Street Central, Hong Kong

## PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Suite 1708, 17/F West Tower, Shun Tak Centre 200 Connaught Road Central Hong Kong

## **Corporate Information**

### PRINCIPAL BANKERS

OCBC Wing Hang Bank Limited

## PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Conyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1–1111 Cayman Islands

### HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited 17/F., Far East Finance Centre 16 Harcourt Road, Hong Kong

### STOCK CODE

2700

### **WEBSITE**

http://www.irasia.com/listco/hk/greeninternational/

# **Condensed Consolidated Statement of Profit or Loss**

For the six months ended 30 June 2022

		For the six months ended 30 June	
		2022	2021
	Notes	HK\$'000	HK\$'000
		(Unaudited)	(Unaudited)
			00.500
Revenue	4	25,037	36,506
Direct costs and operating expenses		(12,802)	(16,684)
0		10.005	10.000
Gross profit		12,235	19,822
Other income and gains, net	5	1,097	197
Selling expenses		(8,571)	(11,643)
Administrative expenses		(15,259)	(18,971)
Gain on disposal of subsidiaries		_	1,900
Finance costs, net	6	(1,548)	(2,352)
Loss before income tax	7	(12,046)	(11,047)
1 12//	0	22	(4.000)
Income tax credit/(expense)	8	69	(1,329)
Loop for the naried		(11.077)	(10.076)
Loss for the period		(11,977)	(12,376)
Loss for the period attributable to:		(0.044)	(10,000)
Equity holders of the Company		(9,844)	(10,636)
<ul> <li>Non-controlling interests</li> </ul>		(2,133)	(1,740)
		(11,977)	(12,376)
		(11,977)	(12,370)
Loss per share for loss for the period attributable to the equity holders of the Company			
Basic and diluted (HK\$ cents)	9	(1.49)	(1.61)
		` '	, - /

# **Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**

For the six months ended 30 June 2022

	For the six months	
	ended 30 June	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Loss for the period	(11,977)	(12,376)
Other comprehensive income, net of tax		
<ul> <li>Exchange differences arising during the period</li> </ul>	(375)	297
Total comprehensive expenses for the period	(12,352)	(12,079)
·	, ,	, ,
Total comprehensive expenses for the period		
attributable to:		
<ul> <li>Equity holders of the Company</li> </ul>	(10,292)	(10,407)
<ul> <li>Non-controlling interests</li> </ul>	(2,060)	(1,672)
	(12,352)	(12,079)

# **Condensed Consolidated Statement of Financial Position**

As at 30 June 2022

	Notes	30 June 2022 <i>HK\$'000</i> (Unaudited)	31 December 2021 <i>HK\$</i> '000 (Audited)
ASSETS Non-current assets Property, plant and equipment Right-of-use assets Trademark user right and technical		9,876 44,034	13,461 51,947
know-how		11,514	11,514
		65,424	76,922
Current assets Inventories Trade receivables Prepayments, deposits and other	11	7,748 5,891	9,319 11,137
receivables Bank balances and cash	12	9,370 104,096	6,692 110,743
		127,105	137,891
Total assets		192,529	214,813
EQUITY Capital and reserves attributable to the equity holders of the Company Share capital Reserves	16	131,979 (76,020)	131,979 (65,728)
Non-controlling interests		55,959 1,004	66,251 3,064
Total equity		56,963	69,315

# Condensed Consolidated Statement of Financial Position

As at 30 June 2022

	Notes	30 June 2022 <i>HK</i> \$'000 (Unaudited)	31 December 2021 <i>HK\$</i> '000 (Audited)
LIABILITIES Non-current liabilities Bonds payables Lease liabilities Deferred tax liabilities	14	5,126 53,963 1,151	4,897 62,912 1,151
		60,240	68,960
Current liabilities Trade payables Contract liabilities Accruals and other payables Lease liabilities Tax payable	13 15	4,561 2,442 55,404 12,904 15	4,255 3,599 56,113 12,552 19
Total liabilities		135,566	145,498
Total equity and liabilities		192,529	214,813
Net current assets		51,779	61,353
Total assets less current liabilities		117,203	138,275

# **Condensed Consolidated Statement of Changes in Equity**

For the six months ended 30 June 2022

	Attributable to the equity holders of the Company						
	Share capital HK\$'000 (Unaudited)	Share premium HK\$'000 (Unaudited)	Exchange reserve* HK\$'000 (Unaudited)	Accumulated losses HK\$'000 (Unaudited)	Total HK\$'000 (Unaudited)	Non- controlling interests HK\$'000 (Unaudited)	Total equity HK\$'000 (Unaudited)
As at 1 January 2021	131,979	895,647	11,634	(904,070)	135,190	6,105	141,295
Total comprehensive income/ (expense) for the period							
Loss for the period Other comprehensive income	-	-	-	(10,636)	(10,636)	(1,740)	(12,376)
for the period		_	229	_	229	68	297
			229	(10,636)	(10,407)	(1,672)	(12,079)
As at 30 June 2021	131,979	895,647	11,863	(914,706)	124,783	4,433	129,216
As at 1 January 2022	131,979	895,647	11,875	(973,250)	66,251	3,064	69,315
Total comprehensive income/ (expense) for the period							
Loss for the period Other comprehensive income/	-	-	-	(9,844)	(9,844)	(2,133)	(11,977)
(expenses) for the period	_	_	(448)		(448)	73	(375)
	<del>_</del> .		(448)	(9,844)	(10,292)	(2,060)	(12,352)
As at 30 June 2022	131,979	895,647	11,427	(983,094)	55,959	1,004	56,963

<sup>\*</sup> The other reserves as presented in the condensed consolidated statement of financial position are comprised of these reserve accounts.

# Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2022

		onths ended lune
	2022	2021
Note	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Net cash generated from/(used in)		
operating activities	1,180	(4,534)
Net cash (used in)/generated from		
investing activities	(71)	409
Net cash used in financing activities	(8,185)	(8,366)
Net decrease in cash and cash		
equivalents	(7,076)	(12,491)
Cash and cash equivalents as at		
1 January	110,743	139,788
Effects of exchange rate changes on		
balances denominated in foreign		/ <b>-</b> >
currencies	429	(747)
Cash and cash equivalents as at 30 June 12	104,096	126,550

#### GENERAL INFORMATION AND BASIS OF PREPARATION 1.

Green International Holdings Limited ("the Company") was incorporated in the Cayman Islands on 8 March 2006 as an exempted company with limited liability. Its registered office is situated at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands. The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") in 2006. Its parent company is Jumbo Faith International Limited ("Jumbo Faith"), which is wholly owned by Ms. Zhou Cuigiong, mother of Mr. Yu Zhouije (a non-executive Director and the Chairman of the Company).

The Company and its subsidiaries (the "Group") was principally engaged in provision of (i) health and medical services and (ii) beauty and wellness products and related services.

These condensed consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (the "HKFRSs") and Hong Kong Accounting Standard 34 "Interim Financial Reporting" as issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

These condensed consolidated financial statements do not include all the information and disclosure required in the annual financial statements, and should be read in conjunction with the Group's audited consolidated financial statements for the year ended 31 December 2021.

These condensed consolidated financial statements have been prepared on a historical cost convention, except as disclosed in the accounting policies and the explanatory notes.

These condensed consolidated financial statements are presented in Group's functional currency, Hong Kong dollars ("HK\$"), and all values are rounded to the nearest thousand ("HK\$'000"), except when otherwise indicated.

## 2. ADOPTION OF NEW AND REVISED HONG KONG FINANCIAL REPORTING STANDARDS

In the current period, the Group has adopted all the new and revised HKFRSs issued by the HKICPA that are relevant to its operations and effective for its accounting year beginning on 1 January 2022. HKFRSs comprise Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards and Interpretations. The adoption of these new and revised HKFRSs did not result in significant changes to the Group's accounting policies, presentation of the Group's financial statements and amounts reported for the current period and prior year except as stated below:

### Application of new and amendments to HKFRSs

In the current period, the Group has applied, for the first time, the following new and amendments to HKFRSs issued by the HKICPA which are mandatory effective for the annual period beginning on or after 1 January 2022 for the preparation of the Group's condensed consolidated financial statements:

Reference to the Conceptual Framework Covid-19-Related Concessions beyond
30 June 2021
30 Julie 202 i
Property, Plant and Equipment — Proceeds
before Intended Use
Onerous contract — Cost of fulfilling a contract
Annual Improvements to HKFRSs 2018-2020

The application of the amendments to HKFRSs in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

#### 3. FINANCIAL RISKS MANAGEMENT AND FINANCIAL **INSTRUMENTS**

The Group's activities expose to a variety of financial risks: foreign exchange risk, credit risk, liquidity risk and cash flow and fair value interest rate risk.

These condensed consolidated financial statements do not include all financial risks management information and disclosures required in the annual financial statements; they should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2021. There have been no material changes in the risk management policies since the year ended 31 December 2021.

### Fair value estimation on a recurring basis

An analysis of financial instruments carried at fair value at the end of each reporting period, by valuation method and at different levels are set out as follows:

- Level 1: Quoted price (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).
- Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).

There were no transfers between Levels 1, 2 and 3 and changes in valuation techniques during the periods.

### 4. REVENUE AND SEGMENT INFORMATION

The Group primarily operates in Hong Kong and the People's Republic of China (the "**PRC**"). The Group's operating businesses are structured and managed separately according to the nature of their operations and the products or services they provide. Each of the Group's business units represents a strategic business unit that offers products or services which are subject to risks and returns that are different from those of the other business units. The Group's business units are as follows:

- (a) the health and medical segment, which is engaged in the operation of health and medical related businesses of its clubhouse, hemodialysis center and hospital; and
- (b) the beauty and wellness segment, which is engaged in selling of beauty and wellness products and related services.

During the six months ended 30 June 2021, the Group discontinued the operation of the financial segment, which was engaged in securities brokerage, advising on securities and asset management businesses, upon the disposal of Green Securities Limited and Green Asset Management Limited.

Operating segments are identified for financial reporting purposes in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Board has been identified as the Group's chief operating decision-maker.

Inter-segment revenue is eliminated on consolidation. Inter-segment sales and transfers are transacted according to the relevant prevailing market prices.

Segment results are presented as operating profit or loss.

#### 4. REVENUE AND SEGMENT INFORMATION (Continued)

Revenue of the Group, together with analysis of the revenue by segments and geographical regions are as follows:

	Health and medical business HK\$'000 (Unaudited)	Beauty and wellness business HK\$'000 (Unaudited)	Others HK\$'000 (Unaudited)	Consolidated  HK\$'000 (Unaudited)
For the six months ended 30 June 2022				
Hong Kong  — At a point in time	-	-	-	-
The PRC  — At a point in time	16,185	8,852	_	25,037
	16,185	8,852	_	25,037
For the six months ended 30 June 2021				
Hong Kong  — At a point in time	-	-	4	4
The PRC  — At a point in time	20,591	15,911	_	36,502
	20,591	15,911	_	36,506

The geographic location analysis of revenue is allocated based on the geographical location of customers and the operating geographic location of the health and medical business and beauty and wellness business. For the six months ended 30 June 2022 and 2021, no single customer's revenue accounted for more than 10% of the Group's total revenue.

### 4. REVENUE AND SEGMENT INFORMATION (Continued)

### 4.2 Results by operating segments are as follows:

	For the six months ended 30 June	
	2022 HK\$'000	<b>2021</b> HK\$'000
	(Unaudited)	(Unaudited)
Health and medical business Beauty and wellness business Others	(2,870) (3,553) –	(2,310) (1,605) (751)
Total operating loss by operating segments	(6,423)	(4,666)
Unallocated corporate expenses, net Gain on disposal of subsidiaries Finance costs, net	(4,075) - (1,548)	(5,929) 1,900 (2,352)
Loss before income tax	(12,046)	(11,047)
Income tax credit/(expense)	69	(1,329)
Loss for the period	(11,977)	(12,376)

#### 4. REVENUE AND SEGMENT INFORMATION (Continued)

4.3 Non-current assets of the Group, excluding financial instruments, by operating segments and geographical regions are as follows:

	Health and medical business HK\$'000 (Unaudited)	Beauty and Wellness Business HK\$'000 (Unaudited)	Unallocated corporate assets HK\$'000 (Unaudited)	Consolidated  HK\$'000  (Unaudited)
As at 30 June 2022				
Hong Kong The PRC	- 39,303	- 25,447	674 -	674 64,750
Segment total non-current assets	39,303	25,447	674	65,424
	Health and medical business HK\$'000 (Audited)	Beauty and wellness business HK\$'000 (Audited)	Unallocated corporate assets HK\$'000 (Audited)	Consolidated  HK\$'000 (Audited)
As at 31 December 2021				
Hong Kong The PRC	- 45,408	- 31,505	9 –	9 76,913
Segment total non-current assets	45,408	31,505	9	76,922

## 5. OTHER INCOME AND GAINS, NET

For the six months ended 30 June		
2022	2021	
HK\$'000	HK\$'000	
(Unaudited)	(Unaudited)	
48	_	
1,049	197	
1,097	197	

Government subsidy Sundry income

## 6. FINANCE COSTS, NET

For the six months ended 30 June 2022 2021 HK\$'000 (Unaudited) (Unaudited)		
(158)	(66)	
229 144 1,333	933 103 1,382	
1,548	2,352	

Interest income:  — Bank deposit
Interest expenses:  — Bonds payable
<ul><li>Other borrowing</li><li>Lease liabilities</li></ul>

#### LOSS BEFORE INCOME TAX 7.

	For the six months ended 30 June	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Depreciation of property, plant and		
equipment	4,383	4,502
Depreciation of right-of-use assets	4,963	4,657
Employee benefit expenses	13,001	17,045

#### **INCOME TAX CREDIT/(EXPENSE)** 8.

Under the two-tiered profits tax rates regime in Hong Kong, the first HK\$2,000,000 of assessable profits of qualifying corporations will be taxed at 8.25%, and assessable profits above HK\$2,000,000 will be taxed at 16.5%. The assessable profits of corporations not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%.

Under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% from 1 January 2008 onwards.

The amounts of income tax credit/(expense) to the condensed consolidated statement of profit or loss are as follows:

		For the six months ended 30 June	
	2022 <i>HK\$'000</i> (Unaudited)	2021 <i>HK</i> \$'000 (Unaudited)	
Current taxation PRC enterprise income tax — Current period	69	(1,329)	
	69	(1,329)	

### 9. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to owners of the Company is based on the following data:

	For the si ended 3 2022 <i>HK\$'000</i> (Unaudited)	
Loss for the purpose of basic and diluted loss per share	(9,844)	(10,636)
	'000	'000
Number of shares Weighted average number of ordinary shares in issue	659,895	659,895
Loss per share Basic and diluted (HK\$ cents)	(1.49)	(1.61)

Note: The weighted average numbers of ordinary shares for the periods ended 30 June 2022 and 2021 had been adjusted for the five-to-one share consolidation of the Company which became effective on 22 January 2021.

### 10. DIVIDENDS

The Directors do not recommend the payment of any dividend for the six months ended 30 June 2022 (for six months ended 30 June 2021: Nil).

### 11. TRADE RECEIVABLES

	30 June 2022 <i>HK</i> \$'000	31 December 2021 <i>HK</i> \$'000
	(Unaudited)	(Audited)
Trade receivables arising from businesses of health and medical services and beauty and wellness products and related		,
services	5,891	11,137

The Group's trade receivables generally have a credit period of 90 days. The maximum credit risk exposure at the end of the reporting period is the carrying amount of the trade receivables. The Group does not have any collateral as security. The Group formulates policies and procedures to ensure the sale of products or services to customers with an appropriate credit history to minimise the credit risk.

### 11. TRADE RECEIVABLES (Continued)

### Ageing analysis

The ageing analysis of trade receivables from business of health and medical services and beauty and wellness products and related services, based on invoice dates, as at 30 June 2022 and 31 December 2021 are as follows:

	30 June 2022 <i>HK\$'000</i> (Unaudited)	31 December 2021 <i>HK\$'000</i> (Audited)
Within 30 days 31—60 days 61—90 days 91—180 days Over 180 days	3,211 1,952 194 259 275	5,156 1,080 1,202 3,496 203
	5,891	11,137

Management assessed the credit quality of the trade receivables in the amount of approximately HK\$5,357,000 (31 December 2021: HK\$7,438,000) that are neither past due nor impaired by reference to the repayment history and financial position of those customers.

### 12. CASH AND BANK BALANCES

	30 June 2022 <i>HK\$'000</i> (Unaudited)	31 December 2021 <i>HK\$'000</i> (Audited)
Bank balances and cash (Note)	104,096	110,743
	104,096	110,743

Note:

Cash and bank balances are denominated in the following currencies:

	30 June	31 December
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Audited)
Hong Kong dollars	89,750	104,913
Renminbi	14,346	5,830
	104,096	110,743

### 13. TRADE PAYABLES

	30 June 2022 <i>HK\$'000</i> (Unaudited)	31 December 2021 <i>HK\$'000</i> (Audited)
Trade payables arising from businesses of health and medical services and beauty and wellness products and related services	4,561	4,255
	4,561	4,255

### Ageing analysis

The ageing analysis of trade payables from business of health and medical services and beauty and wellness products and related services, based on invoice dates, as at 30 June 2022 and 31 December 2021 are as follows:

	30 June	31 December
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Audited)
Within 30 days	1,204	1,934
31-60 days	798	1,496
61-90 days	1,766	279
91-180 days	694	439
Over 180 days	99	107
	4,561	4,255

### 14. BONDS PAYABLES

Details on the movements of the bonds payables for the six months ended 30 June 2022 and the year ended 31 December 2021 are set out as follows:

	HK\$'000
As at 1 January 2021 Interest paid Interest expense Loss on early release of bonds payable Redemption of bond	12,313 (500) 1,162 1,673 (9,751)
As at 31 December 2021 Interest expense	4,897 229
As at 30 June 2022	5,126

The details of the bonds payables in issue as at 30 June 2022 in an aggregate principal amount of HK\$4,000,000 are set out as follows:

On 24 March 2017, the Company entered into a placing agreement with Green Securities Limited ("Green Securities"), pursuant to which Green Securities agreed with the Company to place bonds up to a principal amount of HK\$4,000,000 to a placee who is an independent third party at 100% of the principal amount of the bonds. The bond is denominated in Hong Kong dollars, unsecured, bears interest at 7.15% per annum and will mature on the date falling on the seventh anniversary of the issue of the bond. Interest is payable on the maturity date.

The bond was successfully placed to the placee on the same date. The effective interest rate of the bond was 10.55% to 13.24% per annum.

The fair value of each of the bonds at issue was calculated using market interest rates for equivalent bonds. The difference between the fair value at issue and the net proceeds received was recognized within other income and loss in the condensed consolidated statement of profit or loss.

### 15. ACCRUALS AND OTHER PAYABLES

	30 June 2022 <i>HK\$'000</i> (Unaudited)	31 December 2021 <i>HK\$'000</i> (Audited)
Bond payable (Note(i)) Accruals Other borrowings (Note(ii)) Other payables (Note(iii))	14,835 4,829 4,820 30,920	14,835 7,792 2,746 30,740
	55,404	56,113

#### Notes:

- (i) On 15 April 2016, the Company issued 8% per annum convertible bonds to Hong Kong Qian Hai Financial Group Limited ("HK Qianhai Financial") in an aggregate principal amount of HK\$12,000,000 (the "2016 CB") carrying conversion right to convert into 40,000,000 shares at the conversion price of HK\$0.30 per share (after adjustment) maturing on 15 April 2019. As disclosed in the Company's announcement dated 20 December 2019, the Company was capable and willing to honour its contractual obligations under the Qianhai CB but due to conflicting instructions given Mr. Zhang Xuejun ("Mr. Zhang") and Shenzhen Qianhai Shengzun Hualong Holdings Co., Ltd. ("Shengzun Hualong") as to the recipient of cash payment, the redemption process was delayed without any fault on the part of the Company, pending the resolution of litigation and dispute amongst the various parties. After the date of maturity of the 2016 CB on 15 April 2019, the bond is no longer convertible into shares of the Company. Therefore, the 2016 CB in an aggregate principal amount of HK\$12,000,000 and accrued interest of approximately HK\$2,835,000 was reclassified to accruals and other payables as bond payable in the consolidated statement of financial position.
- (ii) As at 30 June 2022, other borrowings were unsecured loans from independent third parties, unsecured, carrying interest the rate of 8% (2021: 8%) and repayable on demand.
- (iii) As at 30 June 2022, payable to the lessor in respect of leased machineries in the amount of approximately HK\$15,531,000 (2021: HK\$13,537,000) was included in the other payables.

### 16. SHARE CAPITAL

Details on the movements of the share capital for the six months ended 30 June 2022 and the year ended 31 December 2021 are set out as follows:

	Number of shares		Nominal value	
	For the	For the	For the	For the
	six months	year ended	six months	year ended
	ended 30 June	31 December	ended 30 June	31 December
	2022	2021	2022	2021
	Number	Number	HK'000	HK'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Authorised capital:				
As at 1 January	1,000,000,000	5,000,000,000	200,000	200,000
Share consolidation (Note)	-	(4,000,000,000)	-	-
As at 30 June 2022/				
31 December 2021	1,000,000,000	1,000,000,000	200,000	200,000
Issued and fully paid:				
As at 1 January	659,894,693	3,299,473,466	131,979	131,979
Share consolidation (Note)	-	(2,639,578,773)	-	_
As at 30 June 2022/				
31 December 2021	659,894,693	659,894,693	131,979	131,979

Note:

The share consolidation became effective on 22 January 2021 on the basis of every five issued and unissued ordinary shares of par value HK\$0.04 each in the share capital of the Company being consolidated into one consolidated share of par value HK\$0.20 each.

### 17. SIGNIFICANT RELATED PARTY TRANSACTIONS

### Key management compensation

	For the six months ended 30 June	
	<b>2022</b> 202	
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Wages, salaries and other short-term employee benefits Pension costs — defined contribution plans	792 18	1,839 18
	810	1,857

### **BUSINESS REVIEW**

During the six months ended 30 June 2022 (the "**Period**") under review, the Group continued to be principally engaged in the provision of (i) health and medical services and (ii) beauty and wellness products and related services.

#### **Health and Medical Business**

The health and medical business segment (the "Health and Medical Business") of the Group operates its hospital business in Hunnan Province, China through Li County Phoenix Hospital Company Limited ("Phoenix Opco") and Yiyang Zizhong Kidney Disease Hospital Company Limited ("Zizhong Opco") having the medical organisation operating license granted by the local bureau of the National Health Commission to carry out, amongst other permitted medical treatments, hemodialysis treatment.

Since 2021, China has launched the deepening of reform of medicine and healthcare systems, calling for the need of high-quality services under a sound pricing system to guarantee deserved prices for medical services at local hospitals in China. During the Period, the Group's Health and Medical Business continue to face challenges from market competitors. Furthermore, operating overheads of the Health and Medical Business have increased due to the implementation of additional hygiene measures and patient handling procedures to alleviate the threat of the epidemic.

### **Beauty and Wellness Business**

The beauty and wellness business (the "Beauty and Wellness Business") of the Group operates its beauty parlors under the brand name of 瑪莎 (Marsa) in Shenzhen, China through selling of beauty and wellness products and related services to local customers.

The performance of the Beauty and Wellness Business continued to be sluggish during the Period due to the abrupt downturn of the service industry and weakened consumer market as a result of the change in consumption pattern during the epidemic. In addition, during the Period, certain beauty parlors of the Group in Shenzhen were temporarily suspended for business to comply with hygiene control measures under the guidance of local governmental authorities.

### **Prospect**

The prolonged effect of COVID-19 has caused uncertainties of economy and business environment. Going forward, the Group will closely monitor the development of the epidemic and its impact on the Group's businesses, and will take preventive measures to mitigate the impact of the COVID-19 on its businesses. During the second half of 2022, the Group has plans to open, relocate and/or renovate its operation centers in China to put itself in better position for business development as and when the COVID-19 concerns and measures are relaxed in future.

## **Events with Impact to the Financial Position and the Business Operations**

During the Period, certain beauty parlors of the Group in Shenzhen were temporarily suspended for business to comply with certain hygiene control measures under the guidance of local governmental authorities, having impact on the financial position or the business operations of the Group.

### **FINANCIAL REVIEW**

#### Revenue

The Group's revenue for the Period was approximately HK\$25,037,000 (2021: HK\$36,506,000), representing a decrease of approximately 31.42% as compared with the corresponding period last year. The decrease in the revenue was mainly due to uncertainties in the economic and business environment and weakened consumer market in China.

### **Direct Costs and Operating Expenses**

The Group's direct costs and operating expenses for the Period was approximately HK\$12,802,000 (2021: HK\$16,684,000), representing a decrease of approximately 23.27% as compared with the corresponding period of last year. The decrease in the direct costs and operating expenses was generally in line with the decrease in revenue.

### **Gross Profit and Gross Profit Margin**

The Group's gross profit for the Period was approximately HK\$12,235,000 (2021: HK\$19,822,000), representing a decrease of approximately 38.28% as compared with the corresponding period of last year. The Group's gross profit margin for the Period was 48.87% (2021: 54.30%).

### **Selling Expenses**

The Group's selling expenses for the Period amounted to approximately HK\$8,571,000 (2021: HK\$11,643,000), representing a decrease of approximately 26.38% as compared with the corresponding period of last year. The decrease in the selling expenses generally in line with the decrease in revenue.

### **Administrative Expenses**

The Group's administrative expenses for the Period amounted to approximately HK\$15,259,000 (2021: HK\$18,971,000), representing a decrease of approximately 19.57% as compared with the corresponding period of last year. The decrease in the administrative expenses was mainly attributable to implementation of cost control measures.

#### Finance Costs

The Group's finance costs, net for the Period amounted to approximately HK\$1,548,000 (2021: HK\$2,352,000). Details of the finance costs, net are set out in Note (6) to the condensed consolidated financial statements.

#### Loss for the Period

The Group's net loss for the Period was approximately HK\$11,977,000 (2021: HK\$12,376,000).

### **USE OF PROCEEDS OF EQUITY FUND RAISING ACTIVITIES**

The Company had not conducted any equity fund raising activities during the Period.

The amount of proceeds brought forward from issue of equity securities (including securities convertible into equity securities) made in previous financial year(s) and details of the use of such proceeds are set out as below:

Date of announcement	Fund raising activity	Net proceeds raised	Unutilized equity fund raising proceeds brought forward previous periods and the intended use of proceeds	Actual use of proceeds
3 April 2019	The Company issued 754,716,981 ordinary shares to Jumbo Faith at the subscription price of HK\$0.212 per under specific mandate, which was completed on 3 April 2019	Approximately HK\$156 million	Approximately HK\$15 million being set aside for the cash redemption of the 2016 CB maturing in April 2019.	Approximately HK\$15 million continuing to be set aside for the cash redemption of the 2016 CB. Further details are disclosed in the section headed "LITIGATIONS" of this report.
15 December 2020	The Company issued and allotted 1,649,736,733 ordinary shares under the rights issue on the basis of one rights share for every one existing share held on the record date at the subscription price of HK\$0.06 per rights share. The rights issue became unconditional on 9 December 2020	Approximately HK\$95.9 million	As to the remaining net proceeds of HK\$80.9 million for the potential acquisitions, expansion and equipment purchase of the Group's hospital business.	The acquisition and expansion plans of the Group's hospital business have slowed down and the net proceeds have not been utilised by the end of 30 June 2022, due to the deepening of reform of medicine and healthcare systems in 2021 and the prolonged effect of COVID-19 leading to a high degree of uncertainty of economy and business environment.  In the meantime, the Company has slowed down its acquisition or expansion plans, pending the clarification of market reactions under the reform and the

#### LIQUIDITY AND FINANCIAL RESOURCES

As at 30 June 2022, the Group had total assets of approximately HK\$192,529,000 (31 December 2021: HK\$214,813,000) and debts of approximately HK\$76,813,000 (31 December 2021: HK\$83,107,000), giving rise to a leverage ratio (defined as debt to total assets) of approximately 39.90% (31 December 2021: 38.69%).

As at 30 June 2022, the Group had net current assets of approximately HK\$51,779,000 (31 December 2021: HK\$61,353,000), being the surplus of current assets of approximately HK\$127.105.000 (31 December 2021; HK\$137.891.000) over the current liabilities of approximately HK\$75,326,000 (31 December 2021: HK\$76,538,000), giving rise to a current ratio of approximately 1.69 (31 December 2021: 1.80).

As at 30 June 2022, the Group had cash and bank balances of approximately HK\$104.096.000 (31 December 2021: HK\$110.743.000).

### **GEARING RATIO**

As at 30 June 2022, the gearing ratio of the Group (defined as debt to equity) was approximately 137% (31 December 2021: 125%). For this purpose, debt includes bonds payable, other borrowings and lease liabilities.

#### SIGNIFICANT INVESTMENT HELD

The Group had no significant investment held as at 30 June 2022.

#### **ACQUISITION AND DISPOSAL OF SUBSIDIARIES**

The Group had no acquisition and disposal of subsidiaries during the Period.

The Group disposed of the Integrated Financial Business in March 2021 for an aggregate cash consideration of HK\$5,500,000 and recorded a gain on disposal in the amount of approximately HK\$1,900,000.

### **CHARGES ON ASSETS**

None of the Group's assets was pledged to secure any facilities and borrowings granted to the Group as at 30 June 2022.

### **CONTINGENT LIABILITIES**

The Group had no material contingent liabilities as at 30 June 2022.

### FOREIGN EXCHANGE EXPOSURE

The Group's business transactions were mainly carried out in Hong Kong Dollars and Renminbi. The Group was not engaged in any hedging measures during the Period. The Group will regularly review its position and may use financial measures to hedge its foreign currency exposure if it considers the risk to be significant.

### **CAPITAL STRUCTURE**

Details of the changes in the capital structure of the Company for the Period and the year ended 31 December 2021 are summarised below:

## (A) Share Capital

Details of the movements of the share capital for the Period and the year ended 31 December 2021 are set out in Note (16) to the condensed consolidated financial statements.

### (B) Share Options

#### **Old Share Option Scheme**

The old share option scheme (the "Old Share Option Scheme") adopted by the Company on 2 September 2006 lapsed on 2 September 2016 pursuant to the terms of the Old Share Option Scheme. No option was outstanding under the Old Share Option Scheme. After expiry of the Old Share Option Scheme, no further share option would be granted.

#### **New Share Option Scheme**

At the annual general meeting of the Company held on 26 June 2019 (the "2019 AGM"), a new share option scheme (the "New Share Option Scheme") was approved by the shareholders of the Company. The New Share Option Scheme has a lifespan of 10 years. At the 2019 AGM, the Scheme Mandate Limit was approved to allow the Company to grant options for the holders thereof to subscribe up to 147,326,614 shares (before adjustments upon the share consolidations) representing 10% of the shares in issue as the date of approval of the scheme. Details of the New Share Option Scheme are set out in the circular of the Company dated 24 May 2019.

No share options were granted under the New Share Option Scheme for the Period and the year ended 31 December 2021 and there were no outstanding share options as at 30 June 2022 and 31 December 2021. As at the date of this report, the maximum number of options which can be granted under the New Share Option Scheme was 29,465,322 consolidated shares (equivalent to 147,326,614 options before the five-to-one share consolidation took effect on 22 January 2021), representing 4.47% of the existing issued share capital of the Company.

#### **DIVIDENDS**

The Directors do not recommend the payment of any dividend for the Period (2021: Nil).

#### **HUMAN RESOURCES**

As at 30 June 2022, the Group has 182 employees in Hong Kong and China. Employees' remuneration, promotion and salary increments are assessed based on both individuals' and the Group's performance, employees' professional and working experiences and by reference to prevailing market practices and standards.

### LITIGATION

Save as disclosed below, as at the date of this report, neither the Company nor any other member of the Group was engaged in any litigation or claim of material importance known to the Directors to be pending or threatened against any member of the Group:

The Company issued 8% per annum convertible bonds to Hong Kong Qian Hai Financial Group Limited ("HK Qianhai Financial") in an aggregate principal amount of HK\$12,000,000 (the "2016 CB") carrying conversion right to convert into the shares of the Company. The 2016 CB matured on 15 April 2019 without conversion. At or around the maturity date of the 2016 CB, the Company received conflicting instructions from Mr. Zhang Xuejun (張學軍) ("Mr. Zhang") and another entity named 深圳市前海盛尊華龍控股有限公司 (Shenzhen Qianhai Shengzun Hualong Holdings Co., Ltd.) ("Shengzun Hualong"), both purporting to have the authority from the holder of the 2016 CB and each purporting to give different payment instructions to the Company regarding the recipient of the cash redemption amount. Shengzun Hualong commenced legal action against Mr. Zhang, HK Qianhai Financial and the Company (the "Litigation") seeking to recover the cash redemption amount of the 2016 CB. The Company has now received the second instance judgment handed down by Guangdong Shenzhen Intermediate People's Court (the "Court"), confirming the first instance judgment, under which the Court ruled that the subscription agreement in respect of the 2016 CB were entered into with the Company by Mr. Zhang, under the entrustment of Shengzun Hualong and sub-delegating to be entered in the name of HK Qianhai Financial, and ordering the Company to pay the principal and interest in the aggregate amount of RMB12.88 million directly to Shengzun Hualong. The Court also supported the Company's case that the delay in repayment was due to no fault on the part of the Company, such that the Company shall not be responsible for any late penalty. The Court ordered that the late penalty payable to Shengzun Hualong shall be borne by Mr. Zhang. After receiving the above judgment, the Company has instructed its PRC legal adviser to advise the Company on the compliance of the Court's judgment.

## ARRANGEMENT FOR DIRECTORS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed above, at no time during the Period was the Company or any of its subsidiaries a party to any arrangement to enable a Director to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

### **DIRECTORS' INTERESTS IN SHARES**

As at 30 June 2022, the interests or short positions of the Directors and chief executives and their associates in the shares, underlying shares and debenture of the Company and its associated corporations, as recorded in the register maintained by the Company pursuant to Section 352 of the Securities and Futures Ordinance (the "SFO"), or as otherwise notified to the Company and the Stock Exchange of pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code"), were as follows:

## Long positions in shares of the Company and its associated corporations

Name of Director	Capacity in which the shares or underlying shares are held	Long positions in shares	Approximate percentage of total issued shares (Note 2)
Mr. Liu Dong	Beneficial owner and interest of controlled corporation	25,146,000 (Note 1)	3.81%

#### Notes:

- According to the disclosure of interest filings, these 25,146,000 shares deemed to be interested by Mr. Liu Dong ("Mr. Liu") comprised (a) 9,146,000 shares held by Mr. Liu personally; and (b) 16,000,000 shares held by Smoothly Good Investment Development Limited ("Smoothly Good"), a controlled corporation wholly-owned by Mr. Liu. Mr. Liu and Smoothly Good's deemed interests in 16,000,000 Shares here duplicates with each other.
- 2. The percentages are calculated based on the total number of 659,894,693 issued shares as at 30 June 2022. The number of shares illustrated above are after the five-to-one share consolidation which took effect on 22 January 2021.

### SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SHARES

As at 30 June 2022, the following persons (other than a director or chief executive of the Company) had an interest or short position in the shares and underlying shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO:

### Long positions in shares of the Company

Name of substantial shareholder	Capacity in which the shares are held	Long positions in shares	Approximate percentage of total issued shares (Note 3)
Ms. Zhou Cuiqiong	Interest of controlled corporations	370,071,730 (Note 1)	56.08%
Jumbo Faith International Limited	Interest of controlled corporations and beneficial owner	370,071,730 (Note 1)	56.08%
Fluent Robust Limited	Beneficial owner	67,647,058 (Note 1b)	10.25%
Mr. Yu Qigang	Family interests	370,071,730 (Note 2)	56.08%

#### Notes:

- According to the disclosure of interest filings, these 370,071,730 shares deemed to be interested by Zhou Cuiqiong ("Ms. Zhou") and Jumbo Faith International Limited ("Jumbo Faith") comprised:
  - (a) 302,424,672 shares beneficially owned by Jumbo Faith, a controlled corporation whollyowned by Ms. Zhou. Ms. Zhou and Jumbo Faith's deemed interests in 302,424,672 shares duplicated with each other; and
  - (b) 67,647,058 shares beneficially owned by Fluent Robust Limited ("Fluent Robust"), which is a controlled corporation wholly-owned by Jumbo Faith, which is in turn wholly-owned by Mr. Zhou. Ms. Zhou, Jumbo Faith and Fluent Robust's deemed interests in 67,647,058 shares duplicated with each other.
- Mr. Yu Qigang ("Mr. Yu"), as the spouse of Ms. Zhou, is taken to be interested in the 302,424,672 shares held by Jumbo Faith and 67,647,058 shares held by Fluent Robust by virtue of Part XV of the SFO as described in Note 1 above.
- 3. The percentages are calculated based on the total number of 659,894,693 issued shares as at 30 June 2022. The number of shares illustrated above are after the five-to-one share consolidation which took effect on 22 January 2021.

Save as disclosed above, as at 30 June 2022, the Company has not been notified of any other relevant interests or short positions in the issued share capital of the Company which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO.

### PURCHASE, SALE OR REDEMPTION OF SHARES

Neither the Company nor any of its subsidiaries has purchased, sold or redeem any of the Company's securities listed on the Stock Exchange during the Period.

### CORPORATE GOVERNANCE

The Company and the Directors confirm, to the best of their knowledge, that the Company complied with the code provisions set out in the Corporate Governance Code (the "CG Code") as set out in Appendix 14 to the Listing Rules throughout the Period, except the deviation disclosed in the following paragraph:

With respect to Code Provision D.2.5 (formerly C.2.5), an issuer should have an internal audit function and issuers without an internal audit function should review the need for one on an annual basis and should disclose the reasons for the absence of such a function in the Corporate Governance Report. Due to the size and scale of operations, the Group did not have internal audit function during the Period.

The Company has engaged Crowe (HK) Risk Advisory Limited as an external consultant to establish an internal audit function for the Period. The external consultant has assisted the audit committee in carrying out an independent review on the adequacy and effectiveness of the risk management and internal control systems of the Group, and has reported the status of its review to the audit committee on a regular basis. The Group has formulated an internal audit charter to define the scope and duties and responsibilities of the internal audit function and its reporting protocol.

## MODEL CODE ON SECURITIES TRANSACTION BY DIRECTORS

The Company follows the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix 10 to the Listing Rules (the "**Model Code**") as the code of conduct for Directors in their dealings in the Company's securities. Upon specific enquiries by the Company, all Directors have confirmed that have complied with the required standard set out in the Model Code throughout the Period.

#### AUDIT COMMITTEE

As at the date of this report, the audit committee comprises three independent nonexecutive Directors, namely Mr. David Tsoi (Chairman), Mr. Wu Hong and Mr. Wang Chunlin. One out of three audit committee members, Mr. David Tsoi, possesses recognised professional qualifications in accounting and has wide experience in audit and accounting.

The unaudited condensed consolidated financial statements of the Group for the Period have been reviewed by the audit committee of the Company, which is of the opinion that such statements complied with applicable accounting standards and the Listing Rules, and that adequate disclosures have been made.

### **EVENTS AFTER THE REPORTING PERIOD**

The Board is not aware of any significant event requiring disclosure that has taken place subsequent to 30 June 2022 and up to the date of this report.

### **APPRECIATION**

On behalf of the Board, I wish to thank all our shareholders, customers, suppliers and bankers for their continual support. I would also like to extend my appreciation to all the staff for their dedicated work and their contribution throughout the Period.

> By order of the Board **Green International Holdings Limited** Yu Zhouiie Chairman

Hong Kong, 31 August 2022